These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: CoQ10 bioaccessibility and Caco-2 cell uptake improved with novel medium chain triglyceride encapsulation.
    Author: Li Z, Kopec RE.
    Journal: Food Funct; 2024 Nov 11; 15(22):10981-10986. PubMed ID: 39449589.
    Abstract:
    Coenzyme Q10 (CoQ10) serves as a key component of the electron transport chain. Although it can be produced endogenously, genetic mutations and drugs (e.g., statins) limit the amount absorbed, thus dietary sources provide a supplement. The hydrophobicity of CoQ10 limits its absorption during digestion. Encapsulation with medium chain triglycerides (MCTs) + phospholipid improves the water solubility of CoQ10, but the effect on bioaccessibility and Caco-2 cell uptake is understudied. This study compared the bioaccessibility and Caco-2 cell uptake of a powdered CoQ10 (control), as compared to equivalent doses of CoQ10 (2 mg) provided as ubiquinone encapsulated with MCTs + phospholipid in a VitaDry® and VitaSperse® product. Following sample hydration (for the control and VitaDry®) in vitro digestion was conducted. Samples were extracted and CoQ10 quantitated using high performance liquid chromatography-diode array detection (HPLC-DAD). The Vita encapsulated CoQ10 was 1.4× more bioaccessible as compared to the control, with no difference between the VitaDry® and VitaSperse® products. The VitaDry® and VitaSperse® encapsulated CoQ10 was 6.0× and 5.5× better taken up by Caco-2 cells. This study demonstrates that novel MCT and phospholipid based encapsulated CoQ10 is more bioaccessible, and in vitro results support future studies to establish if it may provide a more bioavailable alternative to CoQ10 alone.
    [Abstract] [Full Text] [Related] [New Search]